uniQure (NASDAQ:QURE) Raised to Outperform at Mizuho

uniQure (NASDAQ:QURE) was upgraded by stock analysts at Mizuho from a “neutral” rating to an “outperform” rating in a research report issued to clients and investors on Wednesday, Marketbeat reports. The brokerage currently has a $35.00 price objective on the biotechnology company’s stock, up from their prior price objective of $12.00. Mizuho’s price target would suggest a potential upside of 106.61% from the company’s previous close.

A number of other analysts have also issued reports on the stock. Barclays initiated coverage on shares of uniQure in a research report on Tuesday, January 27th. They set an “equal weight” rating and a $31.00 target price on the stock. Wall Street Zen downgraded uniQure from a “hold” rating to a “sell” rating in a report on Sunday, January 11th. HC Wainwright reissued a “buy” rating and set a $70.00 price target on shares of uniQure in a research note on Tuesday. Stifel Nicolaus set a $14.00 price objective on uniQure in a report on Monday, March 2nd. Finally, TD Cowen reaffirmed a “buy” rating on shares of uniQure in a research report on Tuesday, March 3rd. Ten equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, uniQure has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

uniQure Price Performance

NASDAQ:QURE opened at $16.94 on Wednesday. uniQure has a 12-month low of $7.76 and a 12-month high of $71.50. The firm has a market cap of $1.06 billion, a price-to-earnings ratio of -4.91 and a beta of 0.73. The company’s 50-day moving average is $21.53 and its two-hundred day moving average is $29.49. The company has a current ratio of 10.43, a quick ratio of 10.43 and a debt-to-equity ratio of 0.25.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.93) by $0.37. The business had revenue of $5.57 million during the quarter, compared to the consensus estimate of $4.84 million. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. Research analysts expect that uniQure will post -3.75 EPS for the current year.

Insider Activity

In other news, insider Jeannette Potts sold 3,412 shares of the business’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total transaction of $30,912.72. Following the completion of the sale, the insider directly owned 138,483 shares of the company’s stock, valued at $1,254,655.98. The trade was a 2.40% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Robert Gut sold 25,613 shares of the company’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $24.62, for a total value of $630,592.06. Following the sale, the director owned 32,342 shares of the company’s stock, valued at approximately $796,260.04. The trade was a 44.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 81,399 shares of company stock valued at $1,527,645 in the last ninety days. 4.79% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Private Trust Co. NA purchased a new stake in uniQure during the third quarter valued at about $28,000. Jones Financial Companies Lllp increased its stake in uniQure by 509.0% during the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 509 shares during the last quarter. CIBC Private Wealth Group LLC purchased a new position in shares of uniQure in the 3rd quarter worth about $50,000. Torren Management LLC acquired a new position in shares of uniQure in the 4th quarter valued at about $28,000. Finally, FNY Investment Advisers LLC lifted its stake in shares of uniQure by 76.7% in the 3rd quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 718 shares in the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

Key uniQure News

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Mizuho upgraded uniQure to “outperform” with a $35 price target (up from $12), and multiple firms (RBC, Wells Fargo, Chardan) issued bullish commentary or upgrades this week, supporting short-term buying interest. Mizuho upgrade / coverage roundup
• Positive Sentiment: Royal Bank of Canada and Wells Fargo raised ratings on QURE (coverage noted by AmericanBankingNews), which helped earlier session rallies and increased analyst attention ahead of key drug catalysts. RBC upgrade article
• Neutral Sentiment: Seeking Alpha published an analysis titled “A Unique Situation For UniQure” that dissects catalysts and risks; the piece may influence investors weighing upside vs. regulatory/legal risk but does not present new primary facts. A Unique Situation For UniQure
• Negative Sentiment: Hagens Berman highlighted reports that the FDA publicly rebuked uniQure, alleging the company pushed “distorted” and “manipulated” data for the AMT-130 program — a serious regulatory credibility issue that increases the risk of further clinical/regulatory setbacks and fuels investor concern. Hagens Berman / FDA accusation alert
• Negative Sentiment: Multiple plaintiff law firms (Pomerantz, Bernstein Liebhard, Faruqi, Levi & Korsinsky, Rosen, Kahn Swick & Foti, ClaimsFiler) have filed or solicited investors in securities class actions and are publicizing April lead-plaintiff deadlines — raising potential litigation liability and ongoing headline risk. Pomerantz class action alert Bernstein Liebhard shareholder alert
• Negative Sentiment: HC Wainwright cut near- and multi-year earnings forecasts substantially (Q1–Q4 2026 and FY2026–FY2030 revisions), which signals weaker expected near-term financials and reduces forward EPS visibility despite the firm’s “Buy” rating — a factor pressuring valuation. HC Wainwright estimate revisions (MarketBeat summary)

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.